246 results about "Metabolic syndrome" patented technology

The invention relates to a construction method of a metabolic syndrome phlegm syndrome lipid metabolism characteristic diagnosis model. The construction method comprises the following steps: S1, acquiring a serum sample; s2, carrying out lipid metabolite analysis through a full-quantitative lipidomics formula; s3, carrying out primary screening on differential metabolites; s4, optimizing the characteristic indexes by using a random forest algorithm and stepwise regression; and S5, constructing a differential metabolite diagnosis model through Logistic regression analysis. By analyzing differential lipid metabolites of patients with MetS phlegm syndromes and non-phlegm syndromes, the invention reveals that abnormal accumulation of lipid and lipid metabolites may be the core pathological parenchyma of MetS phlegm syndromes. By integrating lipid metabonomics data, using a random forest algorithm, stepwise regression and other methods to screen feature difference lipid metabolites and construct a MetS phlegm syndrome specific diagnosis model, a novel combined biomarker and evidence-based basis are provided for early diagnosis of MetS phlegm syndromes, and a scientific basis can also be provided for objective diagnosis of traditional Chinese medicine phlegm syndromes.

The invention discloses a polypeptide or a pharmaceutically acceptable salt thereof. The polypeptide has an amino acid sequence as shown in SEQ ID NO: 1 or an amino acid sequence in a conservative modification form thereof. The polypeptide or the pharmaceutically acceptable salt thereof disclosed by the invention can be combined with GLP1R and is used for effectively activating the GLP1R. The GLP1R activating polypeptide is obtained through precise calculation and deep learning model optimization, has a short sequence, has unique amino acid arrangement compared with a traditional GLP-1 analogue, can effectively activate a GLP1R receptor, can also be used for treating or preventing metabolic disorder related diseases, and has a good application prospect. For example, obesity, diabetes, dyslipidemia related diseases, fatty liver diseases, metabolic syndromes, non-alcoholic fatty liver diseases and the like.

The invention relates to the field of medicines, foods or health-care products, in particular to big-fruit hawthorn heteropolysaccharide as well as a preparation method and application thereof. The large-fruit hawthorn heteropolysaccharide is prepared from galacturonic acid, glucuronic acid, mannose, xylose, arabinose, glucose, galactose, fucose and rhamnose. The weight-average molecular weight of the big fruit hawthorn heteropolysaccharide is 81.6 kDa to 157.3 kDa. The product has unique structures of complex monosaccharide composition, low molecular weight, appropriate uronic acid content, low esterification degree and the like; compared with CP which is single in structure and high in esterification, the CP is better in oxidation resistance and bile acid binding capacity; compared with hawthorn polysaccharide with low uronic acid content and high molecular weight, the hawthorn polysaccharide has the advantages that the enzyme inhibition activity is obviously enhanced, and the hawthorn polysaccharide has a wide prospect in development of functional food, health care products or medicines for regulating blood sugar / blood fat, resisting oxidation and preventing metabolic syndromes.

The present invention relates to modulators that can regulate, for example, inhibit the expression and / or activity of an inhibin subunit βE (INHBE), such as double-stranded RNA (dsRNA) active agents or antisense polynucleotide formulations. The present invention also relates to a method for inhibiting the expression and / or activity of INHBE by using such modulators, and a method for preventing and treating INHBE-related diseases in subjects (such as metabolic disorders or obesity or cardiovascular diseases, such as metabolic syndrome).

The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for improving obesity and metabolic syndrome and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15 to 28 parts of radix astragali seu hedysari, 8 to 20 parts of radix codonopsis, 20 to 35 parts of rhizoma dioscoreae, 8 to 24 parts of semen lablab album, 6 to 20 parts of rhizoma atractylodis macrocephalae stir-fried with bran, 20 to 35 parts of raw semen coicis, 3 to 10 parts of rhizoma pinelliae preparata, 6 to 15 parts of pericarpium citri reticulatae, 10 to 20 parts of poria cocos, 6 to 15 parts of rhizoma alismatis, 6 to 15 parts of raw liquorice root, 10 to 20 parts of semen hoveniae, 10 to 20 parts of lotus leaf and 8 to 15 parts of raw fructus crataegi. The composition has the effects of invigorating spleen, replenishing qi, resolving dampness and removing turbidity, can effectively control the weight gain of obese patients and improve the metabolic disorder condition of metabolic syndrome, is safe, effective and stable, has small side effects, and has very good research and development values.

The present invention is directed to substituted 1-(1H-imidazol-1-yl)-3-methyl-2- phenylbutan-2-ol and 1-cyclopentyl-2-(1H-imidazol-1-yl)-1-phenylethan-1-ol compounds useful as agonists of 8-oxo-guanine DNA glycosylase (OGG1) in humans, as well as pharmaceutical compositions comprising them and methods of their use in treating diseases, including metabolic syndrome, obesity, fatty liver disease, dyslipidemia, insulin resistance, neurodegenerative disorders and cancers.

The invention relates to the field of medicine, and discloses a heterocyclic compound with a GLP-1 receptor agonist effect and application of the heterocyclic compound, the heterocyclic compound is a compound with a structure shown in a formula (I), or an isomer, an isotope labeled compound, a prodrug, or pharmaceutically acceptable salt, ester, hydrate or solvate of the compound. The obvious treatment effect is realized in the aspect of reducing blood sugar or reducing weight.

The invention belongs to the technical field of biological medicine, and discloses a pharmaceutical composition for treating metabolic diseases, a preparation method and application, and the pharmaceutical composition comprises edaravone or pharmaceutically acceptable salts thereof and dextroborneol. The weight ratio of the edaravone to the dextroborneol is (10: 1)-(1: 1). The invention finds that the combination of edaravone and dextroborneol shows remarkable curative effects in the aspects of improving cognitive function, reducing blood fat, relieving fatty liver and recovering cardiac function and / or overall metabolic homeostasis; meanwhile, the pharmaceutical composition disclosed by the invention has a remarkable comprehensive treatment effect on metabolic diseases or complications (such as metabolic syndrome) of the metabolic diseases and / or vascular cognitive impairment complicated with the metabolic syndrome.

This invention discloses the application of green tea acidic polysaccharide GTPS in improving metabolic syndrome, aiming to provide a new use for green tea acidic polysaccharide GTPS. The extraction process involves first grinding green tea into powder, boiling, filtering, deproteinizing using the Seval method, concentrating, adding ethanol, allowing it to stand overnight, centrifuging to collect the precipitate, dissolving it, removing the ethanol, and freeze-drying to obtain GTPSs. The GTPSs are then passed through a DEAE-agarose FF column, eluted with distilled water and 0.2, 0.5, and 1.0 mol / L sodium chloride, and the fractions are collected. The fraction eluted with 0.2 mol / L sodium chloride is dialyzed to desalt, yielding green tea polysaccharide GTPS. Applying this to the improvement of metabolic syndrome provides a solid foundation for revealing the key active components in green tea that promote metabolism and paves the way for the future utilization of tea polysaccharides in the pharmaceutical and food industries, offering a promising solution for the integration of tea resources and the application of natural products.

The invention discloses a schizophrenia concurrent metabolic syndrome independent risk factor screening method and system, utilizes a binary logistic regression analysis method to analyze relevance between multi-source factors and concurrent MetS and screen out independent risk factors, and relates to the technical field of medical data processing. According to the schizophrenia concurrent metabolic syndrome independent risk factor screening method and system, the relevance between multi-source factors and concurrent MetS is analyzed through a binary logistic regression analysis method, the independent risk factors are screened out, and a decision tree model is constructed based on the reserved independent risk factors and used for visually displaying and predicting the risk of concurrent MetS of a patient. By comprehensively considering multi-aspect information of the schizophrenia patient and adopting independent risk factor determination and model construction operation, the independent risk factors causing MetS occurrence of the schizophrenia patient are accurately identified, the screening accuracy is improved, meanwhile, the level of MetS concurrent by the patient is predicted, subsequent clinical timely intervention is facilitated, and the risk of MetS occurrence of the schizophrenia patient is reduced. And the MetS concurrent probability of the patient is reduced.

To provide GLP-1R agonistic peptides with reduced GLP-1R agonistic activity, fusion molecules comprising the same and pharmaceutical compositions.SOLUTION: The invention provides a GLP-1R agonistic peptide whose GLP-1R agonistic activity is about 9- to about 531-fold reduced as compared to the GLP-1R agonistic activity of native GLP-1 of a specific sequence. The invention also provides a nucleic acid molecule encoding GLP-1R agonistic peptide with reduced GLP-1R agonistic activity, a pharmaceutical composition comprising a GLP-1R agonistic peptide with reduced GLP-1R agonistic activity and combinations thereof. The pharmaceutical composition is for treating obesity, overweight, metabolic syndrome, diabetes, diabetic retinopathy, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and / or atherosclerosis.SELECTED DRAWING: None

Disclosed herein is a method for treating, preventing, and / or slowing the progression of various chronic inflammatory condition groups including: (1) the Type 2 Diabetes group (Metabolic Syndrome (MET), obesity, hyperglycemia); (2) ARDS (Acute Respiratory Distress Syndrome); (3) chronic autoimmune inflammatory conditions (Rheumatoid Arthritis (RA), Lupus, and Psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolite group-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) eating disorders, such as Prader-Willi Syndrome and other monogenic and symptomatic obesity disorders including leptin pathway defects, each method comprising orally administering a pharmaceutical composition comprising a denatonium salt. The present disclosure is based on the results of a series of studies that tracked biomarker cluster levels to track mediators of inflammatory conditions and mediators of gut signaling hormones in response to orally administered denatonium salts.

Provided is a Bifidobacterium bifidum strain, Bifidobacterium bifidum ibiome001, which can significantly reduce body weight gain and white adipose tissue weight gain of high fat diet-induced obese and diabetic mice, and enhances expression of lipolytic genes ATGL and HSL. Moreover, Bifidobacterium bifidum ibiome001 can significantly lower fasting blood glucose levels, area under curves (AUCs) of the oral glucose tolerance (OGTT) curve, plasma glycated hemoglobin levels and insulin levels of diabetic mice. It is suggested that Bifidobacterium bifidum ibiome001 is a promising potential probiotic strain for the treatment of metabolic syndrome such as obesity, diabetes and the like, which is more effective than other Bifidobacterium strains / compositions.

Disclosed herein are methods for treating metabolic syndrome in a subject using a vitamin D receptor agonist. A preferred vitamin D receptor agonist for the present invention is elocalcitol.

This disclosure presents an auxiliary decision support information generation system and method. One specific implementation of the system includes: a server, various heterogeneous data sources, and at least one terminal; the server is configured to perform the following processes: acquiring a patient information table for cardiorenal metabolic syndrome, wherein the patient information table includes individual patient identifiers; creating and updating a knowledge graph for cardiorenal metabolic syndrome; generating a standardized set of medical event records for each patient identifier; generating an initial spatiotemporal graph of medical events; determining the generated initial spatiotemporal graphs of medical events as an initial spatiotemporal graph set, and storing the initial spatiotemporal graph set; generating a spatiotemporal graph of medical events corresponding to the patient's medical data; generating auxiliary decision support information; and sending the auxiliary decision support information to the terminal. This implementation reduces the scheduling resources of the medication dispensing robot.

The invention relates to the technical field of traditional Chinese medicine pharmacy, and discloses a traditional Chinese medicine composition for reducing uric acid and application thereof, and the traditional Chinese medicine composition comprises the following components in parts by mass: 15-20 parts of ash bark, 20-25 parts of clerodendranthus spicatus, 18-22 parts of astragalus membranaceus, 12-15 parts of prepared polygonum multiflorum, 15-18 parts of rhizoma smilacis glabrae, 8-10 parts of ligusticum wallichii, 10-12 parts of roasted rhizoma atractylodis macrocephalae and 10-15 parts of salt-fried semen plantaginis. The preparation method comprises the three steps of segmented extraction, sustained-release pellet forming and preparation forming. The traditional Chinese medicine composition disclosed by the invention has the high-efficiency performance of reducing uric acid, protecting healthy qi and achieving long-term effect, and can regulate and control a uric acid metabolic pathway in a multi-target manner; the product can be widely applied to the fields of products for treating primary hyperuricemia and gout in a sustained-release period, products for improving hyperuricemia metabolic syndrome, health-care tea for hyperuricemia and high-risk people, gel products for relieving red, swollen and heat pain of joints in an acute attack period of gout and the like, and the preparation process is controllable and easy to industrialize.

The application discloses a GLP-1 / GIP receptor dual agonist and application thereof. The amino acid sequence general formula of the GLP-1 / GIP receptor dual agonist polypeptide compound is as follows: Tyr-Xaa1-Glu-Gly-Thr-Xaa2-Thr-Asn-Asp-Xaa3-Ser-Ile-Xaa4-Leu-Asp-Lys-Ile-Ala-Gln-Xaa5-Xaa6-Phe-Val-Gln-Trp-Leu-Xaa7-X aa8 -NH2. The application also relates to derivatives, long-acting compounds, pharmaceutically acceptable salts, pharmaceutical compositions and medicaments of the polypeptide compound. The GLP-1 / GIP receptor dual agonist polypeptide compound has more potential in preparation of drugs for treating metabolic syndrome and other diseases.

The invention provides a traditional Chinese medicine composition which comprises the following components in parts by weight: 32-34 parts of rumex hanus, 20-31 parts of dandelion, 20-32 parts of uncaria rhynchophylla and 15-35 parts of gastrodia elata. And at least one of the following six traditional Chinese medicines in parts by weight: 17-37 parts of radix paeoniae alba, 15-20 parts of lumbricus, 10-45 parts of eucommia ulmoides, 22-34 parts of longan seeds, 20-37 parts of tribulus terrestris and 10-30 parts of herba siegesbeckiae. The traditional Chinese medicine composition is taken by adopting deuterium-depleted water. The combination of the traditional Chinese medicinal materials has a synergistic effect in the aspects of treating hypertension, hyperlipidemia and metabolic syndrome, the traditional Chinese medicinal materials respectively contain different active ingredients, the overall curative effect is enhanced by regulating blood pressure, blood fat and metabolic functions through multiple targets, and in order to enable the traditional Chinese medicinal composition to better exert the drug effect, the traditional Chinese medicinal composition has a remarkable curative effect. Preferably, the deuterium-depleted water is matched with the traditional Chinese medicine composition to be taken, and the effect of the deuterium-depleted water is developed by 1-2 times.

The present disclosure relates to compositions and methods of using the same for the treatment of various metabolic diseases and related disorders (e.g. diabetes mellitus, NAFLD, obesity, metabolic syndrome). The compositions and methods of the disclosure relate to the administration of an arginine-degrading enzyme.

The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as Prader-Willi syndrome, obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain, weight loss, and / or reduction in fatty tissue, and a marked decrease in lipid synthesis and accumulation.

Provided here relates to use of Akkermansia muciniphila or a composition containing Akkermansia muciniphila in preparation of a pharmaceutical composition or a health care product composition for improving metabolic syndrome. The Akkermansia muciniphila is Akkermansia muciniphila AM06, Akkermansia muciniphila AM02, or a combination thereof, the deposit number of Akkermansia muciniphila AM06 being CGMCC No. 22793, and the deposit number of the Akkermansia muciniphila AM02 being CGMCC No. 22794. The improvement of a metabolic syndrome comprises preventing and / or treating the metabolic syndrome.

The present application relates to the formula shown with BCA Tm agonist effect 2- (amino carbonyl) -1H-indole-5-carboxamide derivatives, its racemate or optical isomer, its solvate, or its pharmaceutically acceptable salt, and its use in the preparation of treating metabolic syndrome or obesity drugs and the use of pharmaceutical compositions containing them. Wherein, R1 is the following substituent group amide, methanol, methyl sulfonamide.

The invention discloses a metabolic syndrome multi-index collaborative management system and method, relates to the technical field of medical health management, and aims to solve the problems of multi-index dispersed monitoring, lack of collaborative intervention and insufficient individuation in existing metabolic syndrome management. The system comprises a data acquisition module (for acquiring multiple indexes such as blood glucose, blood pressure, blood fat, BMI and the like and user behavior information), a preprocessing module (for denoising standardization), a collaborative analysis module (for analyzing index correlation and risk levels based on random forest / logistic regression), a personalized intervention module (for generating diet / exercise / medication suggestions) and a doctor-patient interaction module (for generating diet / exercise / medication suggestions). Data synchronization and online consultation; a data storage module (encrypted storage); the method corresponds to the steps. According to the method, isolated monitoring is replaced by multi-index collaborative analysis, a personalized scheme is generated in combination with individual characteristics, doctor-patient real-time linkage is achieved, management compliance and intervention accuracy are improved, the risk of metabolic syndrome complications is effectively reduced, and the method is suitable for clinical and home health management.

The application discloses a metabolic marker for distinguishing metabolic syndrome and simple obesity and application thereof. The marker comprises eight metabolites, i.e. glycocholic acid, lithocholic acid, linoleic acid, valine, leucine, alanine, serine and glycine. The application performs non-targeted metabolomics analysis on serum of metabolic syndrome and simple obesity patients by liquid chromatography mass spectrometry, finds eight metabolites with significant difference between the two, and finds that the eight metabolic markers have high AUC when used for diagnosing and distinguishing metabolic syndrome patients or simple obesity patients alone or in combination.

The present disclosure relates to, inter alia, compositions and pharmaceutical composition s, including heterologous chimeric proteins that find use, inter alia, in the treatment of diabetes, obesity, or metabolic syndrome.

The invention relates to application of guaiacol or a derivative thereof in preparation of a medicine for preventing or treating metabolic syndrome, and belongs to the technical field of medicines. The guaiacol and the derivative thereof provided by the invention have the advantages that by regulating a fat metabolism pathway, the insulin resistance condition is obviously improved, the inflammatory response and oxidative stress injury are relieved, and the prevention and treatment on the metabolism-related fatty liver disease (MASLD), hyperlipidemia, hypercholesteremia, obesity and diabetes mellitus are realized through the synergistic effect of multiple dimensions.

Disclosed are compounds of Formula I: wherein A, B, D, X, R1, R2 and R8 are as defined herein, or salts thereof, which have the properties of antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I, or salts thereof, and methods of treating cardiovascular diseases and conditions associated with PCSK9 activity, such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or associated cardiovascular diseases and cardiovascular metabolic conditions.

The present disclosure provides methods and materials related to MANPs. In one embodiment, the present disclosure provides a method for treating hypertension with metabolic syndrome by administering MANPs to a patient in need of such treatment. In one embodiment, the present disclosure provides a method comprising administering MANPs to a patient to lower blood pressure (BP). In one embodiment, the method of the present disclosure is employed to treat patients with low baseline cGMP levels. In one embodiment, the present disclosure provides a therapeutic method using MANPs to increase or improve plasma cGMP levels, plasma ANP-like peptide levels, insulin sensitivity, or plasma NEFA levels. In one embodiment, the present disclosure provides a therapeutic method using MANPs to lower plasma glucose levels.

The invention discloses a method for promoting conversion of rare ginsenoside in gynostemma pentaphylla and a therapeutic effect of a prepared product on metabolic syndrome. Specifically, the invention discloses a method for promoting conversion of rare ginsenoside in gynostemma pentaphylla, and the method comprises the following steps: (1) taking a proper amount of gynostemma pentaphylla medicinal material dried in the shade, crushing, and adding water for infiltration; (2) soaking for a period of time at a certain water bath temperature; (3) evaporating to dryness, adding ethanol or methanol with a certain concentration, carrying out heating reflux extraction or ultrasonic extraction, cooling an extracting solution, filtering, and carrying out vacuum concentration to obtain a concentrate; and (4) loading the concentrate on macroporous resin, adsorbing, eluting, and collecting the 60-80% ethanol elution part to obtain the total saponins dried in the shade. The method is mild in reaction condition, high in efficiency, high in specificity and free of pollution, and the prepared product is high in rare ginsenoside content and can be used for preventing and / or treating metabolic diseases such as non-alcoholic fatty liver diseases.